Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Vanguard High Dividend Yield ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Vanguard High Dividend Yield ETF trades at $159.16 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 13.4× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is more actively traded (1,441,031 versus 1,062,392). Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Vanguard High Dividend Yield ETF for 140 Days on average.
| SYRE | VYM | |
|---|---|---|
Market Cap | $7.52B | $100.80B |
Volume | 1,441,031 | 1,062,392 |
Sector | Health | — |
52-Week High | $108.92 | $167.03 |
52-Week Low | $22.18 | $138.43 |
Typical Hold Time | 0 Days | 140 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
VYM trades at $159.11, down slightly by 0.08% on the day. The ETF shows a bullish technical signal overall, with moving averages supporting an uptrend, though oscillators are neutral. Recent news highlights its consistent dividend yield of 2.42% but questions its performance versus peers like SCHD and IDV. Key support sits at $158, with resistance at $160.
The outlook for VYM hinges on its dividend reliability amid competition from higher-yielding or better-performing ETFs. Risks include exposure to dividend cuts in holdings like Intel and Walgreens. Analyst sentiment is mixed, favoring a hold rating due to moderate returns compared to alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
